Evidence mapPaperPMID 42017188Full record

ArticleInternational journal of women's health2026

Sex Differences in Long COVID Prevalence Over One year After the Acute Phase, and Related Risk Factors. The GINA-COVID Cohort Study.

Mar Alvarez-Pedrerol, Sara Polo-Alonso, Rafel Ramos, Ruth Martí-Lluch, Mel Lina Pinsach-Abuin, Irene R Dégano, Roberto Elosua, Isaac Subirana, Álvaro Hernáez, Elisabet Selga and 14 more

Abstract read
In one paragraph

Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Evolutionary Predictors of Post-COVID Syndrome.Journal of clinical medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Mar Alvarez-PedrerolRegistre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.
Sara Polo-AlonsoRegistre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.
Rafel RamosMedical Science Department, School of Medicine, University of Girona, Girona, Spain.ORCID 0000-0001-7970-5537
Ruth Martí-LluchVascular Health Research Group, Institut Universitari per a la Recerca en Atenció Primària Jordi Gol I Gurina, Girona, Spain.ORCID 0000-0002-7320-9521
Mel Lina Pinsach-AbuinCardiovascular Genetics Center, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IdIBGi), Salt, Spain.ORCID 0000-0001-7199-512X
Irene R DéganoRegistre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.ORCID 0000-0003-1914-6934
Roberto ElosuaFaculty of Medicine, University of Vic-Central University of Catalonia, Vic, Spain.
Isaac SubiranaCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Álvaro HernáezRegistre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.
Elisabet SelgaFaculty of Medicine, University of Vic-Central University of Catalonia, Vic, Spain.
Eulàlia PuigdecanetFaculty of Medicine, University of Vic-Central University of Catalonia, Vic, Spain.
Josefina Pruneda-PazRegistre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.
Clàudia Solà-RicharteRegistre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.
Marta PuigmuléCardiovascular Genetics Center, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IdIBGi), Salt, Spain.
Alexandra PérezCardiovascular Genetics Center, Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IdIBGi), Salt, Spain.
Xavier NoguésMusculoskeletal Research Unit, Hospital del Mar Research Institute, Barcelona, Spain.
Joan Ramon MasclansCritical Illness Research Group (GREPAC), Hospital del Mar Research Institute, Barcelona, Spain.ORCID 0000-0002-0809-6823
Roberto Güerri-FernándezMedicine and Life Sciences Department, Universitat Pompeu Fabra (UPF), Barcelona, Spain.
Héctor Cubero-GallegoBiomedical Research in Heart Diseases Group, Hospital del Mar Research Institute, Barcelona, Spain.
Helena Tizon-MarcosCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Beatriz VaquerizoCentro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain.
Ramon BrugadaMedical Science Department, School of Medicine, University of Girona, Girona, Spain.
Anna Camps-Vilaró *Registre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.ORCID 0000-0001-9644-8421
Jaume Marrugat *Registre Gironí del Cor (REGICOR) Study Group, Hospital del Mar Research Institute, Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: This 1-year cohort study aimed to track long COVID prevalence, identify associated risk factors, and assess its association with hospitalization. Methods: The GINA-COVID cohort study included 2698 COVID-19 patients from Spain, who reported persistent symptoms spontaneously mentioned in an open questionnaire one year after infection. We recorded symptom onset, duration, and recovery rates at 12 months. Hospitalization data were collected from the Catalan Health System. We performed descriptive statistics and logistic regression models stratified by sex to identify factors associated with long COVID, using multiple imputation for missing values and model selection via stepwise regression based on the Akaike Information Criterion. Results: Significant sex differences appeared, with females showing a two-fold higher risk of developing long COVID compared to males (OR=1.95; 95% CI, 1.68-2.29). Females reported higher prevalence and a greater number of persistent symptoms, with fatigue being the most common in both sexes (36% in females, 26% in males at 3 months). The recovery rate at 12 months was lower in females (23% vs. 34%, p<0.001). Hypertension emerged as the most significant protective factor for long COVID in females (OR=0.64; 95% CI, 0.48-0.84), whereas COVID-19 severity was the most influential risk factor in males (OR=2.34; 95% CI, 1.79-3.08). Despite these differences, the trajectory of persistent symptoms over time was similar between the sexes. Importantly, long COVID did not increase hospital admissions. Conclusion: Findings underscore the importance of sex-specific approaches in managing long COVID and suggest further investigation into hypertension's protective role in females and disease severity's impact in males.

Indexed as

long COVIDpersistent symptomprevalencerisk factorsSARS-CoV-2sex differences

Identifiers

PMID42017188
PMCPMC13094581

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.